Vedolizumab induces remission in more than 30% of UC patients with chronic pouchitis

Vedolizumab more effectively induced remission compared with placebo in patients with chronic pouchitis following ileal pouch-anal anastomosis for ulcerative colitis, according to research in The New England Journal of Medicine.“Idiopathic inflammation of the pouch — referred to as pouchitis — is the most common long-term complication of ileal pouch-anal anastomosis (IPAA); it develops in approximately half of patients within 5 years after undergoing IPAA and recurs in more than 50% of affected patients,” Simon Travis, DPhil, professor of clinical gastroenterology atRead More

Generated by Feedzy